MO751OXIDATIVE STRESS IN PATIENTS WITH CHRONIC RENAL FAILURE AND CARDIOVASCULAR COMPLICATIONS

Background and Aims The atherosclerosis process is highly accelerated in patients with chronic kidney disease (CKD). Oxidative stress is considered as one of the pro-atherogenic factors involved in accelerating the atherosclerosis process of the carotid artery. The aim of the present study was to determine the relationship between oxidative stress markers and the progression of carotid atherosclerosis in CKD patients. Method The study was conducted on 220 patients with CKD and 40 controls, and the disease stage was scored between 2 and 5D. Blood samples were taken and myeloperoxidases, malondialdehyde, nitric oxide, glutathione, and oxidised low-density lipoprotein were measured. Furthermore, we studied the correlations between these biomarkers and clinical and para-clinical cardiovascular complications. Results The average age of patients was 60.5 years. The oxidative stress markers average ± SD levels in CKD groups compared to the control were as follows: myeloperoxidase (49.89 ±1.98 vs. 38.45 ±1.98 UI/ml), malondialdehyde (5.2 ±0.12 vs. 3.26 ±0.03 µmol/l), nitric oxide (56.82 ±1.06 vs. 42.19 ±2.1 µmol/l), glutathione (42.21 ±1.3 vs. 79.4 ±2.6 IU/ml), and oxLDL (15.57 ±1.07 vs. 1.72 ±0.82 µmol/l). While the glutathione level decreased significantly in advanced CKD stage (p < 0.05), the concentrations of all the other biomarkers increased significantly in accordance with CKD score (p < 0.05). Patients with high IMD (> 1 mm) had higher values of the prooxidant markers (NO, oxLDL, MDA, MPO) but lower antioxidant marker values (glutathione), compared to other patients with lower IMD Conclusion Cardiovascular diseases, mainly atherosclerosis, can be diagnosed indirectly by measuring oxidative stress markers. Furthermore, theses markers can be used to predict the progression of CKD, for better management of the disease.

Obesity and cardio-metabolic health

Obesity is a major and growing global health problem. It is associated with increased mortality as a result of an increasing number of complications, including type 2 diabetes, dyslipidaemia, hypertension, non-alcoholic hepatic steatosis, cardiovascular disease, sleep apnoea, gallbladder disease, obesity-related renal disease, increased risk of falls and injuries, and mental health problems as well as increased risk of certain malignancies. This article discusses the metabolic derangements associated with obesity. These include insulin resistance, dysglycaemia, low and dysfunctional high-density lipoprotein, formation of small dense and oxidised low-density lipoprotein, and high circulating levels of free fatty acids. This article reviews the aetiology of these derangements and their relationship to cardiovascular disease, and discusses the concept of metabolic health.